// App-Quantinova.ai

: Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Researchers

Presenter

  • Sergio Rutella

Principal Investigators

  • John Muth

  • Mary Elizabeth Mathyer

  • Alun James Carter

  • Brunda Tumala

  • Laura Arthur

  • Kristann Magee

  • Paula Comune Pennacchi

  • Julian Gorrochategui

  • Vincent Petit

  • Daniel Primo

  • Dominique Blanchard

  • Michael Kiebish

  • Nupur Bhatnagar

  • David Boocock

  • Jayakumar Vadakekolathu

  • Matthew L Cooper

  • Melissa M. Berrien-Elliott

  • Jan K Davidson-Moncada

  • Todd A. Fehniger

Medical Centers

  • Berg Health, Framingham, MA

  • Vivia Biotech, Madrid, Spain

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

  • Wugen, St. Louis, MO

  • Department of Medicine, Washington University School of Medicine, Saint Louis, MO

  • Vivia Biotech, Tres Cantos, Spain

  • Metafora Biosystems, Paris, France

  • John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom

Locations

  • United States

  • France

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 25

  • Cluster of differentiation 69

  • Cluster of differentiation 7

  • Granzyme B

  • Interferon regulatory factor 9

  • Interleukin 6 Receptor

  • Immune cells

  • NLR family pyrin domain containing 3

Drug/Treatment

  • Interferon

  • NK 101

Outcome

  • N/A

Study Design

  • Investigator Initiated

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved